IDEAYA Biosciences, Inc. (IDYA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$158.8M
Cash & Equivalents
$75.2M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$3,517M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | PHASE2 | Recruiting | 262 |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | PHASE1 | Recruiting | 260 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-01 | 8-K | IDEAYA Biosciences, Inc. (IDYA) (CIK 0001676725) - 8-K | EDGAR |